Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CUE |
---|---|---|
09:32 ET | 4720 | 1.07 |
09:33 ET | 11900 | 1.06 |
09:35 ET | 2171 | 1.05 |
09:37 ET | 2000 | 1.05 |
09:39 ET | 1937 | 1.0403 |
09:42 ET | 200 | 1.05 |
09:44 ET | 1500 | 1.0542 |
09:46 ET | 169 | 1.055 |
09:48 ET | 900 | 1.06 |
09:50 ET | 1742 | 1.07 |
09:51 ET | 600 | 1.07 |
09:53 ET | 4000 | 1.07 |
09:55 ET | 673 | 1.07 |
10:02 ET | 3900 | 1.06 |
10:04 ET | 1667 | 1.0508 |
10:08 ET | 1062 | 1.0552 |
10:15 ET | 900 | 1.065 |
10:18 ET | 700 | 1.06 |
10:22 ET | 4584 | 1.075 |
10:24 ET | 10700 | 1.07 |
10:26 ET | 300 | 1.06 |
10:31 ET | 6519 | 1.045 |
10:33 ET | 1238 | 1.05 |
10:36 ET | 3200 | 1.055 |
10:38 ET | 4400 | 1.055 |
10:42 ET | 800 | 1.055 |
10:44 ET | 3200 | 1.05 |
10:47 ET | 7200 | 1.05 |
10:49 ET | 1500 | 1.055 |
10:51 ET | 1500 | 1.05 |
10:54 ET | 1765 | 1.04 |
10:56 ET | 1750 | 1.0458 |
11:00 ET | 3200 | 1.045 |
11:02 ET | 100 | 1.05 |
11:05 ET | 588 | 1.04 |
11:07 ET | 9600 | 1.04 |
11:09 ET | 1600 | 1.045 |
11:12 ET | 100 | 1.05 |
11:14 ET | 300 | 1.04 |
11:16 ET | 2629 | 1.045 |
11:18 ET | 580 | 1.04 |
11:20 ET | 10000 | 1.04 |
11:21 ET | 11871 | 1.0306 |
11:23 ET | 8900 | 1.0301 |
11:25 ET | 2620 | 1.03 |
11:27 ET | 1000 | 1.04 |
11:30 ET | 1466 | 1.04 |
11:32 ET | 3450 | 1.04 |
11:34 ET | 300 | 1.04 |
11:38 ET | 800 | 1.05 |
11:39 ET | 2400 | 1.04 |
11:41 ET | 500 | 1.04 |
11:43 ET | 3000 | 1.045 |
11:45 ET | 620 | 1.045 |
11:56 ET | 2743 | 1.06 |
11:57 ET | 184 | 1.0698 |
11:59 ET | 100 | 1.065 |
12:01 ET | 3100 | 1.07 |
12:03 ET | 900 | 1.06 |
12:06 ET | 1000 | 1.06 |
12:08 ET | 1500 | 1.06 |
12:17 ET | 1400 | 1.0701 |
12:19 ET | 1000 | 1.06 |
12:24 ET | 200 | 1.065 |
12:33 ET | 4256 | 1.075 |
12:37 ET | 300 | 1.075 |
12:39 ET | 100 | 1.07 |
12:44 ET | 1940 | 1.075 |
12:46 ET | 1300 | 1.08 |
12:51 ET | 2302 | 1.0831 |
12:55 ET | 210 | 1.085 |
01:06 ET | 9200 | 1.0813 |
01:08 ET | 100 | 1.08 |
01:11 ET | 18342 | 1.095 |
01:13 ET | 100 | 1.09 |
01:15 ET | 2500 | 1.095 |
01:18 ET | 2178 | 1.09 |
01:22 ET | 100 | 1.08 |
01:24 ET | 100 | 1.08 |
01:29 ET | 1000 | 1.08 |
01:31 ET | 994 | 1.09 |
01:33 ET | 1400 | 1.085 |
01:38 ET | 100 | 1.08 |
01:40 ET | 400 | 1.08 |
01:45 ET | 1283 | 1.0839 |
01:47 ET | 776 | 1.08 |
01:49 ET | 1722 | 1.08 |
01:51 ET | 100 | 1.08 |
01:54 ET | 200 | 1.08 |
01:56 ET | 500 | 1.08 |
01:58 ET | 300 | 1.08 |
02:02 ET | 3408 | 1.08 |
02:03 ET | 400 | 1.08 |
02:12 ET | 355 | 1.07 |
02:14 ET | 100 | 1.07 |
02:16 ET | 100 | 1.07 |
02:20 ET | 100 | 1.07 |
02:21 ET | 100 | 1.0701 |
02:23 ET | 300 | 1.075 |
02:25 ET | 800 | 1.08 |
02:27 ET | 250 | 1.09 |
02:30 ET | 1316 | 1.095 |
02:32 ET | 1900 | 1.0901 |
02:34 ET | 800 | 1.09 |
02:38 ET | 765 | 1.08 |
02:39 ET | 200 | 1.08 |
02:41 ET | 317 | 1.0804 |
02:45 ET | 200 | 1.085 |
02:48 ET | 875 | 1.08 |
02:50 ET | 100 | 1.08 |
02:52 ET | 900 | 1.08 |
02:54 ET | 500 | 1.08 |
02:56 ET | 100 | 1.08 |
02:57 ET | 200 | 1.08 |
02:59 ET | 100 | 1.08 |
03:01 ET | 1200 | 1.08 |
03:03 ET | 9400 | 1.08 |
03:08 ET | 600 | 1.08 |
03:10 ET | 300 | 1.08 |
03:12 ET | 398 | 1.08 |
03:14 ET | 100 | 1.08 |
03:19 ET | 600 | 1.08 |
03:21 ET | 500 | 1.08 |
03:24 ET | 13314 | 1.075 |
03:26 ET | 100 | 1.075 |
03:30 ET | 3100 | 1.07 |
03:32 ET | 400 | 1.075 |
03:35 ET | 100 | 1.07 |
03:39 ET | 100 | 1.07 |
03:42 ET | 100 | 1.07 |
03:44 ET | 1230 | 1.07 |
03:46 ET | 4507 | 1.075 |
03:48 ET | 300 | 1.0726 |
03:50 ET | 2400 | 1.07 |
03:51 ET | 18845 | 1.07 |
03:53 ET | 33034 | 1.05 |
03:55 ET | 51795 | 1.055 |
03:57 ET | 10650 | 1.0378 |
04:00 ET | 74586 | 1.03 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cue Biopharma Inc | 62.0M | -1.1x | --- |
Kronos Bio Inc | 52.7M | -0.6x | --- |
Atara Biotherapeutics Inc | 60.1M | -0.4x | --- |
Armata Pharmaceuticals Inc | 76.0M | -1.7x | --- |
CervoMed Inc | 79.1M | -6.0x | --- |
Dyadic International Inc | 49.2M | -7.6x | --- |
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $62.0M |
---|---|
Revenue (TTM) | $9.5M |
Shares Outstanding | 60.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.67 |
EPS | $-0.91 |
Book Value | $0.79 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 6.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -479.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.